The PI3K/AKT signaling pathway is a target for cancer treatment owing to its hyperactivation in tumor cells, and the protein expression levels of PI3K and p-AKT are inhibited by metformin or everolimus in some common cancers, including cervical cancer [56,72,73,74]. Here, AKT1 is linked to neoplasm.